title: Intensive therapy with peripheral stem cell transplantation in 16 patients with mantle cell lymphoma.
abstract: BACKGROUND
  Despite improved detection of mantle cell lymphoma (MCL), results of its treatment with conventional therapies remain disappointing and the survival rate poor. The role of high-dose chemotherapy has recently been investigated but no potential benefit has been clearly established. We report here our experience with MCL patients treated with intensive chemotherapy and autologous stem cell transplantation (ASCT).
  
  
  METHODS
  Of the 16 MCL patients who received high-dose chemotherapy and ASCT beginning in 1989, six were treated in first-line and 10 in sensitive relapse. Twelve of 16 patients received regimens which included total body irradiation. All patients received peripheral blood stem cells (PBSC) with the exception of one, who underwent bone marrow transplantation.
  
  
  RESULTS
  Three patients died of toxic effects of treatment, Three months after transplant, seven achieved complete response, (CR) and two partial responses (PR), two were stable and two had progressed. With a median follow-up after transplant of 22 months, five of the six surviving patients were without progression, and three were in CR. The median times for event-free survival (EFS) and overall survival (OS) were, respectively, 249 and 317 days. The expected three-year EFS and OS were 24%. The median survival after diagnosis was only 29 months. None of the criteria appeared to be significantly associated with a better outcome, but first-line intensification and a short delay after initial diagnosis may be favorable.
  
  
  CONCLUSIONS
  In this study we were not able to confirm the hypothetical benefit of high-dose chemotherapy and PBSC transplantation in mantle cell lymphoma, even though this approach may be promising in a subgroup of patient.
authors.affiliation: Service d'Hématologie, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, France.
authors.forename: N
authors.initials: N
authors.lastname: Ketterer
authors.forename: G
authors.initials: G
authors.lastname: Salles
authors.forename: D
authors.initials: D
authors.lastname: Espinouse
authors.forename: C
authors.initials: C
authors.lastname: Dumontet
authors.forename: E M
authors.initials: EM
authors.lastname: Neidhardt-Berard
authors.forename: I
authors.initials: I
authors.lastname: Moullet
authors.forename: F
authors.initials: F
authors.lastname: Bouafia
authors.forename: F
authors.initials: F
authors.lastname: Berger
authors.forename: P
authors.initials: P
authors.lastname: Felman
authors.forename: B
authors.initials: B
authors.lastname: Coiffier
mesh_terms: D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D016019:Survival Analysis
chemical_list: D018906:Antineoplastic Agents, Alkylating; D005047:Etoposide; D003520:Cyclophosphamide